Figure 2
Comparison of the recurrence-free survival rates between HCC patients with EGV who received SR and RFA as a primary treatment modality.
Figure 2 | Scientific Reports
Comparison of the recurrence-free survival rates between HCC patients with EGV who received SR and RFA as a primary treatment modality.
